Scientists engineered a bioengineered viral delivery system that performs RNA editing directly in macrophages to modulate sepsis responses, according to a Nature Communications report. The approach combines chemogenetic control with RNA-targeting effectors to reprogram innate immune cells in situ. Authors showed functional edits in macrophages in animal models and evidence of improved outcomes in sepsis experiments. In vivo, cell-targeted RNA editing offers a route to transiently rewire immune effectors without permanent genomic alteration.